-
My Account
In App
My Account
BSE Live
Jan 20, 11:18Prev. Close
6141.25
Open Price
6163.15
Bid Price (Qty.)
6114.50 (2)
Offer Price (Qty.)
6122.25 (7)
NSE Live
Jan 20, 11:18Prev. Close
6140.00
Open Price
6142.50
Bid Price (Qty.)
6118.50 (1)
Offer Price (Qty.)
6119.50 (2)
| Cash Flow of Divis Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 102.31 | 101.96 | |
| Net CashFlow From Operating Activities | 37.89 | 26.98 | |
| Net Cash Used In Investing Activities | -26.32 | -35.93 | |
| Net Cash Used From Financing Activities | -14.27 | 12.09 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -2.70 | 3.14 | |
| Cash And Cash Equivalents Begin of Year | 4.49 | 1.35 | |
| Cash And Cash Equivalents End Of Year | 1.79 | 4.49 |
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Neutral Divis Laboratories; target of Rs 6925: Motilal Oswal
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
